References

  1. A.I. Schäfer, A.G. Fane and T.D.Waite, Nanofiltration – Principles and Applications, Elsevier Oxford, UK, 2005.
  2. N. Bolong, A review of the effects of emerging contaminants in waste water and options for their removal, Desalination, 239 (2009) 229-246.
  3. S-Z. Li, X-Y. Li and D-Z. Wang, Membrane (RO-UF) filtration for antibiotic wastewater treatment and recovery of antibiotics, Sep. Purif. Technol., 34 (2004) 109-114.
  4. K. Kosutic, D. Dolar, D. Asperger and B. Kunst, Removal of antibiotics from a model wastewater by RO/NF membranes, Sep. Purif. Technol., 53 (3) (2007) 244-249.
  5. R.M. Sharpe and D.S. Irvine, How strong is the evidence of a link between environmental chemicals and adverse effects on human health? Br. Med. J., 323 (2001) 447-451.
  6. T. Heberer, Occurrence, fate, and removal of pharmaceuticals residues in the aquatic environment: a recent research data, Toxicol. Lett., 131 (2002) 5-17.
  7. P. Xu, J.E. Drewes, C. Bellona, G. Amy, T.U. Kim, M. Adam and T. Heberer, Rejection of emerging organic micropollutants in nanofiltration-reverse osmosis membrane applications, Water Environ. Res.,
    77 (2005) 40-48.
  8. K. Kimura, S. Toshima, G.A. Amy and Y. Watanabe, Rejection of neural endocrine disrupting compounds (EDCs) and pharmaceutical active compounds (PhACs) by RO membranes, J. Membr. Sci., 245 (2004) 71-78.
  9. T.U. Kim, G. Amy and J.E. Drewes, Rejection of trace organic compounds by high pressure membranes, Water Sci. Technol., 51 (2005) 335-344.
  10. Y. Yoon, P. Westerhoff, S.A. Snyder and E.C. Wert, Nanofiltration and ultrafiltration of endocrine disrupting compounds, pharmaceuticals and personal care products, J. Membr. Sci., 270 (2006) 88-100.
  11. Y. Yoon, P. Westerhoff, S.A. Snyder, E.C. Wert and J. Yoon, Removal of endocrine disrupting compounds and pharmaceuticals by nanofiltration and ultrafiltration membranes, Desalination, 202 (2007) 16-23.
  12. S.A. Snyder, S. Adham, A.M. Redding, F.S. Cannon, J. DeCarolis, J. Oppenheimer, E.C. Wert and Y. Yoon, Role of membranes and activated carbon in the removal of endocrine disruptors and pharmaceuticals, Desalination, 202 (2007) 156-181.
  13. A.G. Fane, Sustainability and membrane processing of wastewater for reuse, Desalination, 2002 (2007) 53-58.
  14. A.M. Comerton, R.C. Andrews, D.M. Bagley and C. Hao, The rejection of endocrine disrupting and pharmaceutically active compounds by NF and RO membranes as a function of compound and water matrix properties, J. Membr. Sci., 313 (2008) 323-335.
  15. S.D. Kim, J. Cho, I.S. Kim, B.J. Vanderford and S.A. Snyder, Occurrence and removal of pharmaceuticals and endocrine disruptors in South Korean surface, drinking and waste waters, Water Res.,
    41 (5) (2007) 1013-1021.
  16. L. Braeken, R. Ramaekers, Y. Zhang, G. Maes, B. Van der Bruggen and C. Vandecasteele, Influence of hydrophobicity on retention in nanofiltration of aqueous solutions containing organic compounds, J. Membr. Sci., 252 (2005) 195-203.
  17. HyperChem, Standard Release 5.11 for Windows, Molecular Modelling System, Hypercube Inc., Waterloo, Ontario, 1999.
  18. S. Babic, D. Asperger, D. Mutavdzic, A.J.M. Horvat and M. Kastelan-Macan, Solid phase extraction and HPLC determination of veterinary pharmaceuticals in wastewater, Talanta, 70 (2006) 732-738.
  19. Standard Methods for the Examination of Water and Waste Water, 19th ed., APHA, AWWA, American Public Health Association, Washington, 1995.
  20. B. Kunst, K. Kosˇutic´, Removal of emerging contaminants in water treatment by nanofiltration and reverse osmosis, D. Barcelo and M. Petrovic, eds., Hdb, Env, Chem., Springer-Verlag, Berlin, Heidelberg, vol. 5, Part 5S/2, 2008, pp. 103-125.
  21. K. Kosutic, D. Dolar and B. Kunst, On experimental parameters characterizing the reverse osmosis and nanofiltration membranes’ active layer, J. Membr. Sci., 282 (2006) 109-114.